Innovation & SciencePipeline
Otsuka Pharmaceutical collaborates actively with leading-edge academia and venture companies, in addition to using conventional drug discovery methods.
This open sharing of ideas enables us to develop unique compounds.
Psychiatry & Neurology
Code / <Brand name>
Generic name
Indication
Country / Region
Development status
(Phase I, II, III, Filed / Approved)
(Phase I, II, III, Filed / Approved)
<ABILIFY MAINTENA*>
aripiprazole
Bipolar
JP
Filed
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
* Product names used outside Japan
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Major depressive disorder
JP, EU, China
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Schizophrenia
China
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Agitation associated with dementia of the Alzheimer's type
JP, US, EU
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Bipolar I disorder
US, EU
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Posttraumatic stress disorder
US, EU
Phase II
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Schizophrenia
US
Phase I
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Features: Dopamine partial agonist
Dosage form: Depot injection
OPC-64005
Attention deficit hyperactivity disorder
US
Phase II
Origin: Otsuka Pharmaceutical
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Agitation associated with dementia of the Alzheimer's type
US, EU
Phase III
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Negative symptoms of schizophrenia
US
Phase II/III
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Traumatic brain injury
US
Phase II
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Intermittent explosive disorder
US
Phase II
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
EB-1020
centanafadine
Attention deficit hyperactivity disorder
US
Phase III
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
TEV-48125
fremanezumab
Migraine
JP
Phase II/III
Origin: Teva
Features: Anti-CGRP antibody
Dosage form: Injection
Features: Anti-CGRP antibody
Dosage form: Injection
Oncology
Code / <Brand name>
Generic name
Indication
Country / Region
Development status
(Phase I, II, III, Filed / Approved)
(Phase I, II, III, Filed / Approved)
SGI-110
guadecitabine
Ovarian cancer
US, EU
Phase II
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
SGI-110
guadecitabine
Acute myeloid leukemia
JP, US, EU
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
SGI-110
guadecitabine
Myelodysplastic syndrome
JP, US, EU
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
ASTX727
Myelodysplastic syndrome
US
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Features: DNA methyltransferase inhibitor
Dosage form: Oral
ASTX727
Myelodysplastic syndrome
JP
Phase I
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Features: DNA methyltransferase inhibitor
Dosage form: Oral
ASTX660
Solid tumors, Lymphomas
US
Phase II
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
Features: IAP inhibitor
Dosage form: Oral
ASTX029
Solid tumors
US
Phase I/II
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
ASTX295
Solid tumors
US
Phase I/II
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
OPB-111077
Solid tumors, Hematological cancers
US
Phase I
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Dosage form: Oral
TBI-1401
canerpaturev
Pancreatic cancer
JP
Phase I
Origin: Takara Bio
Features: Oncolytic Virus
Dosage form: Injection
Features: Oncolytic Virus
Dosage form: Injection
TBI-1301
Synovial sarcoma
JP
Phase I/II
Origin: Takara Bio
Features: NY-ESO-1 siTCR® gene therapies
Dosage form: Injection
TBI-1501
Acute lymphoblastic leukemia
JP
Phase I/II
Origin: Takara Bio
Features: CD19 CAR gene therapies
Dosage form: Injection
Features: CD19 CAR gene therapies
Dosage form: Injection
Cardiovascular & Renal areas
Code / <Brand name>
Generic name
Indication
Country / Region
Development status
(Phase I, II, III, Filed / Approved)
(Phase I, II, III, Filed / Approved)
OPC-41061<Samsca>
tolvaptan
Syndrome of inappropriate antidiuretic hormone secretion
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Oral
Features: V2 -receptor antagonist
Dosage form: Oral
OPC-61815
Cardiac edema
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Injection
Features: V2 -receptor antagonist
Dosage form: Injection
AKB-6548
vadadustat
Anemia associated with chronic kidney disease
US, EU
Phase III
Origin: Akebia
Features: HIF-prolyl hydroxylase inhibitor
Dosage form: Oral
Features: HIF-prolyl hydroxylase inhibitor
Dosage form: Oral
Other therapeutic areas
Code / <Brand name>
Generic name
Indication
Country / Region
Development status
(Phase I, II, III, Filed / Approved)
(Phase I, II, III, Filed / Approved)
OPC-67683<Deltyba>
delamanid
Multidrug-resistant tuberculosis
US
Phase III
Origin: Otsuka Pharmaceutical
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
OPC-167832
Tuberculosis
US
Phase I/II
Origin: Otsuka Pharmaceutical
Features: DPrE1 inhibitor
Dosage form: Oral
OPA-15406
difamilast
Atopic dermatitis
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: PDE4 inhibitor
Dosage form: Ointment
OPS-2071
Clostridium difficile infection, enteric infection
JP
Phase II
Origin: Otsuka Pharmaceutical
Features: New quinolone based antibacterial agent
Dosage form: Oral
Features: New quinolone based antibacterial agent
Dosage form: Oral
VIS410
Influenza A infection
US
Phase II
Origin: Visterra
Features: Anti-hemagglutinin monoclonal antibody
Dosage form: Injection
C13-CAC
Measurement of gastric acidity
JP
Phase II
Origin: Otsuka Pharmaceutical
Features: 13C-calcium carbonate breath test
Dosage form: In-vivo diagnostic agent
Features: 13C-calcium carbonate breath test
Dosage form: In-vivo diagnostic agent
Code / <Brand name>
Generic name
Indication
Country / Region
Development status
(Phase I, II, III, Filed / Approved)
(Phase I, II, III, Filed / Approved)
<ABILIFY MAINTENA*>
aripiprazole
Bipolar
JP
Filed
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
* Product names used outside Japan
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Major depressive disorder
JP, EU, China
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Schizophrenia
China
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Agitation associated with dementia of the Alzheimer's type
JP, US, EU
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Bipolar I disorder
US, EU
Phase III
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Agitation associated with dementia of the Alzheimer's type
US, EU
Phase III
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
EB-1020
centanafadine
Attention deficit hyperactivity disorder
US
Phase III
Origin: Neurovance
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
Features: Norepinephrine, dopamine and serotonin reuptake inhibitor
Dosage form: Oral
SGI-110
guadecitabine
Acute myeloid leukemia
JP, US, EU
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
SGI-110
guadecitabine
Myelodysplastic syndrome
JP, US, EU
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
ASTX727
Myelodysplastic syndrome
US
Phase III
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Features: DNA methyltransferase inhibitor
Dosage form: Oral
OPC-41061<Samsca>
tolvaptan
Syndrome of inappropriate antidiuretic hormone secretion
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Oral
Features: V2 -receptor antagonist
Dosage form: Oral
OPC-61815
Cardiac edema
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: V2 -receptor antagonist
Dosage form: Injection
Features: V2 -receptor antagonist
Dosage form: Injection
AKB-6548
vadadustat
Anemia associated with chronic kidney disease
US, EU
Phase III
Origin: Akebia
Features: HIF-prolyl hydroxylase inhibitor
Dosage form: Oral
Features: HIF-prolyl hydroxylase inhibitor
Dosage form: Oral
OPC-67683<Deltyba>
delamanid
Multidrug-resistant tuberculosis
US
Phase III
Origin: Otsuka Pharmaceutical
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
Features: Mycolic acid biosynthesis inhibitor
Dosage form: Oral
OPA-15406
difamilast
Atopic dermatitis
JP
Phase III
Origin: Otsuka Pharmaceutical
Features: PDE4 inhibitor
Dosage form: Ointment
AVP-786
deuterium-modified dextromethorphan, quinidine
Negative symptoms of schizophrenia
US
Phase II/III
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
TEV-48125
fremanezumab
Migraine
JP
Phase II/III
Origin: Teva
Features: Anti-CGRP antibody
Dosage form: Injection
Features: Anti-CGRP antibody
Dosage form: Injection
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Posttraumatic stress disorder
US, EU
Phase II
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Oral
Features: Dopamine partial agonist
Dosage form: Oral
OPC-64005
Attention deficit hyperactivity disorder
US
Phase II
Origin: Otsuka Pharmaceutical
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
Features: Serotonin, norepinephrine and dopamine reuptake inhibitor
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Traumatic brain injury
US
Phase II
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
AVP-786
deuterium-modified dextromethorphan, quinidine
Intermittent explosive disorder
US
Phase II
Origin: Avanir
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
Features: NMDA receptor antagonist / Serotonin and norepinephrine reuptake inhibitor / Sigma-1 receptor agonist
Dosage form: Oral
SGI-110
guadecitabine
Ovarian cancer
US, EU
Phase II
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Injection
Features: DNA methyltransferase inhibitor
Dosage form: Injection
ASTX660
Solid tumors, Lymphomas
US
Phase II
Origin: Astex
Features: IAP inhibitor
Dosage form: Oral
Features: IAP inhibitor
Dosage form: Oral
OPS-2071
Clostridium difficile infection, enteric infection
JP
Phase II
Origin: Otsuka Pharmaceutical
Features: New quinolone based antibacterial agent
Dosage form: Oral
Features: New quinolone based antibacterial agent
Dosage form: Oral
VIS410
Influenza A infection
US
Phase II
Origin: Visterra
Features: Anti-hemagglutinin monoclonal antibody
Dosage form: Injection
C13-CAC
Measurement of gastric acidity
JP
Phase II
Origin: Otsuka Pharmaceutical
Features: 13C-calcium carbonate breath test
Dosage form: In-vivo diagnostic agent
Features: 13C-calcium carbonate breath test
Dosage form: In-vivo diagnostic agent
ASTX029
Solid tumors
US
Phase I/II
Origin: Astex
Features: ERK1/2 inhibitor
Dosage form: Oral
ASTX295
Solid tumors
US
Phase I/II
Origin: Astex
Features: MDM2 inhibitor
Dosage form: Oral
TBI-1301
Synovial sarcoma
JP
Phase I/II
Origin: Takara Bio
Features: NY-ESO-1 siTCR® gene therapies
Dosage form: Injection
TBI-1501
Acute lymphoblastic leukemia
JP
Phase I/II
Origin: Takara Bio
Features: CD19 CAR gene therapies
Dosage form: Injection
Features: CD19 CAR gene therapies
Dosage form: Injection
OPC-167832
Tuberculosis
US
Phase I/II
Origin: Otsuka Pharmaceutical
Features: DPrE1 inhibitor
Dosage form: Oral
OPC-34712<REXULTI / RXULTI>
brexpiprazole
Schizophrenia
US
Phase I
Origin: Otsuka Pharmaceutical
Features: Dopamine partial agonist
Dosage form: Depot injection
Features: Dopamine partial agonist
Dosage form: Depot injection
ASTX727
Myelodysplastic syndrome
JP
Phase I
Origin: Astex
Features: DNA methyltransferase inhibitor
Dosage form: Oral
Features: DNA methyltransferase inhibitor
Dosage form: Oral
OPB-111077
Solid tumors, Hematological cancers
US
Phase I
Origin: Otsuka Pharmaceutical
Dosage form: Oral
Dosage form: Oral
TBI-1401
canerpaturev
Pancreatic cancer
JP
Phase I
Origin: Takara Bio
Features: Oncolytic Virus
Dosage form: Injection
Features: Oncolytic Virus
Dosage form: Injection
- Note: In general, Otsuka disclose compounds that are in Phase II or later stage of development, although some compounds in Phase I are disclosed in the above table.
(as of September 30, 2019)
Other Innovation & Science contents
Original Research & Development
Otsuka takes a holistic approach to people's health and well-being through its two core businesses of pharmaceuticals and nutraceuticals. Aiming to find cures for diseases and to maintain and promote people's health, we continue to take the untraveled path in research and development.
As part of our inquisitive research culture, Otsuka Pharmaceutical also enters into "horizontal collaborations" in which we harmonize with, as equals, bioventures and academic institutions. Aligning our own drug discovery resources with external knowledge and technologies multiplies our collective capacity for pathbreaking innovation.
